Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)

Fondation Ophtalmologique Adolphe de Rothschild

Status: Completed

Conditions: Corticobasal Degeneration; Progressive Supranuclear Palsy

Treatments: Drug: Apomorphine

Study type: Observational

Funder types: NETWORK

Identifiers

NCT04786158

CE_20200204_5_CHH

Details and patient eligibility

About

Treatment of tauopathies such as Progressive Supranuclear Palsy (PSP) and Cortico Basal Degeneration (CBD) remains a major challenge. These rare severe neurodegenerative extrapyramidal movement disorders share phenotypic overlap and are usually painful. Parkinson disease (PD) is a common extrapyramidal movement disorder and continuous subcutaneous apomorphine infusion (CSAI) is commonly used in advanced PD patients to alleviate motor and non-motor fluctuations. Effects of subcutaneous apomorphine were investigated especially on pain and, on quality of life in 7 patients with PSD or CBD.This is an observational "real life" surveillance-based study.The Verbal Rating Scale for Pain (VRS) was used to assess changes in pain level and the clinical global impression-improvement scale (CGI-I) was used to assess changes in patient's illness before and during six months of treatment. Detailed report of the symptoms and side effects has been recorded by home nurses throughout the study period.

Enrollment: 7 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• PSP or CBD patients for whom a treatment with subcutaneaous apomorphine is indicated

Exclusion criteria

• Pregnant or breastfeeding women
• Patient under a legal protection procedure
• Patient denying to participated to the study
• Lack of affiliation to a social security system